Core Viewpoint - The U.S. Federal Trade Commission has issued an early termination notice regarding Eli Lilly's acquisition of Ventyx Biosciences, indicating regulatory approval for the transaction [1] Group 1: Transaction Details - Eli Lilly plans to acquire all outstanding shares of Ventyx Biosciences for $14 per share, valuing the total equity of the transaction at approximately $1.2 billion [1] - The completion of the transaction is expected in the first half of 2026 [1]

Group 1 - In 2025, a total of 6.763 million marriage registrations were recorded in China, an increase of 657,000 compared to the previous year, representing a growth of 10.76% [3][4] - The new marriage registration regulations effective from May 10, 2025, will eliminate regional restrictions and allow nationwide processing of marriage certificates [3][4] - The increase in marriage registrations is particularly notable in cities with high influxes of migrant populations [3] Group 2 - Elon Musk was ranked as the greatest innovator in the Forbes "Innovators 250" list, with Nvidia CEO Jensen Huang placed fifth [4] - The top ten innovators include notable figures such as Jeff Bezos, Bill Gates, and George Lucas [4] - The U.S. stock market saw a collective decline, with major tech stocks like Apple dropping by 5% [4] Group 3 - The CEO of Insta360, Liu Jingkang, announced the distribution of five apartments and several luxury cars as incentives during the company's annual meeting [2][3] - The total value of the cars given away exceeded 10 million yuan, highlighting the importance of material incentives for employee motivation [2] Group 4 - The Chinese market for high-end talent is increasingly influenced by both intrinsic motivations like achievement and extrinsic incentives such as material rewards [2] - The introduction of a "low-quality seat" reminder by the 12306 ticketing platform has sparked discussions among consumers regarding the quality of available seating options [2] Group 5 - Samsung Electronics has begun mass production of HBM4 memory and is actively expanding its production capacity, anticipating a threefold increase in sales compared to 2025 [7] - Nuveen is set to acquire Schroders for £9.9 billion, marking the end of the latter's 200-year independence [7] Group 6 - LV, Dior, and Tiffany were fined over 36 billion KRW in South Korea due to poor management of customer information leading to data leaks [12] - The fines were imposed by the Personal Information Protection Commission, with LV facing the largest penalty of 21.385 billion KRW [12] Group 7 - SoftBank Group reported a net profit increase to 3.1726 trillion yen for the period from April to December 2025, marking a fivefold increase compared to the previous year [20] - Hermes announced a revenue of 16 billion euros for 2025, reflecting a 5.5% year-on-year growth [20] - Siemens reported a net profit of 2.222 billion euros for the first quarter of 2026, a decrease of 43% year-on-year [20]

| 指数 | 收盘 | | 涨跌（％） | | | --- | --- | --- | --- | --- | | 名称 | （点） | 1 日 | 5 日 | 1 月 | | 上证指数 | 4134 | 0.05 | -0.75 | 1.43 | | 深证综指 | 2709 | 0.51 | -0.21 | 2.2 | 2026 年 02 月 13 日 映恩生物-B（9606.HK）深度：差异化 ADC 技术平台，2026 年催化剂丰富 ◼ 映恩生物是一家以差异化 ADC 技术平台为核心的创新生物药公司。依托自 主研发的四大领先 ADC 技术平台：DITAC、DIBAC、DIMAC 及 DUPAC， 公司已构建覆盖 HER2、HER3、TROP2、B7-H3 等靶点的多款核心 ADC 管线，同时布局双抗 ADC、全新机制载荷 ADC、自免 ADC 等下一代产品， 适应症涵盖乳腺癌、肺癌、前列腺癌等多个瘤种。 ◼ 多款创新管线达成全球授权合作，全面推进 ADC+IO 2.0 联合疗法。 ◼ DB-1311（B7-H3 ADC）适应症覆盖广泛，2026 年多项数据读出。 ◼ 构建创新 2.0 管线，聚焦下一代 ...

据英国《新科学家》网站11日报道，全球首款针对肺癌的吸入式基因疗法，在临床试验中展现出积极疗 效，已获美国食品药品监督管理局（FDA）授予"再生医学先进疗法认定"，进入快速审批通道，有望加 速上市惠及患者。 ...

Group 1 - The core viewpoint of the article is that Shenzhen Yimufeng Biotechnology Co., Ltd. has submitted an application for listing on the Hong Kong Stock Exchange, with Huatai International as its sole sponsor [1] - Yimufeng Biotechnology is described as a global leader in innovative cell therapy, focusing on its core product IMC002, which is a potential best-in-class anti-CLDN18.2 CAR-T cell therapy candidate [1] - The IMC002 therapy is currently in a critical clinical phase (Phase III clinical trial) and is noted to be the second in clinical progress globally among solid tumor CAR-T therapy candidates [1]

经济观察网 新桥生物（NBP.OQ）近期股价下跌与高管增持计划同时出现，主要受以下因素影响： 股价与资金表现 2026年1月20日，新桥生物执行董事长傅唯宣布计划以个人资金增持不超过500万美元公司股份（约合人 民币3500万元）。然而，公司日均成交额仅约300万美元，增持规模相对市场流动性较大，短期可能放 大抛压。2026年2月9日至12日，股价连续下跌，累计跌幅达10.95%，其中2月12日单日下跌4.42%，收 报3.24美元，成交额仅79万美元，显示资金承接力较弱。 公司2025年第二季度财报显示，营业收入为0美元，归母净利润亏损552万美元，基本每股收益-0.07美 元，且尚未有产品实现商业化。尽管核心管线Givastomig在一线胃癌治疗中取得客观缓解率77%等积极 数据，但市场担忧其从临床成果到收入转化的周期较长。叠加生物技术板块整体波动（纳斯达克指数同 期下跌2.03%），投资者信心受基本面压制。 公司基本面 2024年，新桥生物曾因CD47靶点药物来佐利单抗被艾伯维"退货"，导致公司剥离中国业务以缓解对赌 压力，历史合作风险仍影响市场预期。尽管高管增持传递长期信心，但公司截至2025年累计亏 ...

Financial Data and Key Metrics Changes - As of December 31, 2025, the company had a cash balance of approximately $7 million [13] - Consolidated operating expenses for Q3 2026 were approximately $2.06 million, an increase of $250,000 or 13.6% compared to the same period last year [13] - Operating loss for the quarter increased to $2.06 million compared to $1.81 million in the prior year period [13] - For the nine-month period, operating expenses decreased significantly to $5.36 million, down $1.98 million or 27% from $7.34 million last year [15] Business Line Data and Key Metrics Changes - The company is advancing its Hemopurifier platform while maintaining disciplined cost control [5] - Continued enrollment and treatment progress in the Australian oncology trial, with two patients treated in the second cohort [7][29] - The R&D team is exploring the Hemopurifier's compatibility with a simplified blood treatment system, which could enhance clinical and commercial flexibility [10] Market Data and Key Metrics Changes - There has been an uptick in the number of interested potential participants in the Australian oncology trial since contracting with Trialfacts and Dedicated [8] - The trial is designed to examine the number of Hemopurifier treatments needed to decrease extracellular vesicle concentrations and improve the body's ability to attack tumor cells [9] Company Strategy and Development Direction - The company aims to advance the Hemopurifier platform while managing costs effectively [5] - The focus remains on the Australian oncology trial, with no plans to expand to other markets like India at this time [75][81] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the ongoing progress in the oncology trial and the potential for the Hemopurifier to serve multiple indications [11][29] - The company is committed to maintaining cost containment while advancing its research and development efforts [27] Other Important Information - The scientific rationale and full design of the Australian oncology trial have been published in a peer-reviewed journal [10] - The next earnings call for fiscal Q4, ending March 31, 2026, will coincide with the filing of the annual report in June 2026 [16] Q&A Session Summary Question: Clarification on Cohort 2 treatment duration - The follow-up period remains the same, but participants in Cohort 2 will receive two Hemopurifier treatments instead of one [18][19] Question: Impact of SLAMB system on treatment administration - The SLAMB system would allow for a less invasive treatment method, making it easier for both hospital staff and patients [20][23] Question: Cost-effective approach in R&D - The company is focused on keeping costs down while advancing research, utilizing in-house resources as much as possible [26][27] Question: Timeline for Data Safety Monitoring Board's decision - The board is expected to provide a decision on advancing to the third cohort on the same day or the next business day after their meeting [36] Question: Need for Cohort 3 - Management believes it is essential to investigate Cohort 3 to determine if three treatments could yield better results than two [62] Question: Regulatory hurdles for SLAMB system integration - The SLAMB system is not yet approved, and the company would need to conduct safety tests before integration [46][47] Question: Future trials in India - The company is currently focused on the Australian trial and does not plan to return to India for additional trials [75][81]

Financial Data and Key Metrics Changes - As of December 31, 2025, the company had a cash balance of approximately $7 million [13] - Consolidated operating expenses for the three months ended December 31, 2025, were approximately $2.06 million, an increase of $250,000 or 13.6% compared to the same period last year [13] - The operating loss for the quarter increased to $2.06 million compared to $1.81 million in the prior year period [13] - For the nine-month period, operating expenses decreased significantly to $5.36 million, down $1.98 million or 27% from $7.34 million last year [15] Business Line Data and Key Metrics Changes - The company is advancing its Hemopurifier platform while maintaining disciplined cost control [5] - Continued enrollment and treatment progress in the Australian oncology trial, with two Hemopurifier treatments completed in the second cohort [7][9] - The R&D team is exploring the compatibility of the Hemopurifier with a simplified blood treatment system, which could enhance clinical and commercial flexibility [10] Market Data and Key Metrics Changes - There has been an uptick in the number of interested potential participants in the Australian oncology trial since contracting with TrialFax and Dedicated for advertising and pre-screening [8] - The study is designed to examine the number of Hemopurifier treatments needed to decrease extracellular vesicle concentrations and improve the body's ability to attack tumor cells [9] Company Strategy and Development Direction - The company is focused on advancing the Hemopurifier platform and exploring its potential as a multi-indication therapeutic [5] - The integration of the Hemopurifier with the SLAMB system could facilitate its use in oncology units and infusion centers, reducing invasiveness for patients [23][24] - The company aims to build on preclinical data in Long COVID and explore other indications related to extracellular vesicles [11][12] Management's Comments on Operating Environment and Future Outlook - Management emphasized the importance of cost containment while advancing clinical trials and R&D efforts [27] - The company is currently focused on completing the Australian trial and is not planning to expand to other regions like India at this time [75][78] Other Important Information - The next earnings call for the fiscal fourth quarter, ending March 31, 2026, will coincide with the filing of the annual report in June 2026 [16] Q&A Session Summary Question: Clarification on Cohort 2 treatment duration - The follow-up period remains the same, but participants in Cohort 2 will receive two Hemopurifier treatments instead of one [19] Question: Impact of SLAMB system on treatment administration - The SLAMB system would allow for a less invasive catheter insertion, making it easier for patients and hospital staff to administer treatments [24] Question: Cost-effective approach in R&D - The company is trying to keep costs down by conducting work in-house and limiting outside lab involvement while still advancing research [27] Question: Timeline for Data Safety Monitoring Board's decision - The board is expected to provide a decision on advancing to the third cohort on the same day or the next business day after their meeting [36] Question: Need for Cohort 3 - Management believes it is important to investigate the third cohort to assess the potential benefits of three treatments compared to two [62] Question: Regulatory hurdles for SLAMB system integration - The SLAMB system is not yet approved, and the company would need to conduct safety tests before using it with the Hemopurifier [47]

Financial Data and Key Metrics Changes - As of December 31, 2025, the company had a cash balance of approximately $7 million [13] - Consolidated operating expenses for Q3 2026 were approximately $2.06 million, an increase of $250,000 or 13.6% compared to the same period last year [13] - The operating loss for the quarter increased to $2.06 million compared to $1.81 million in the prior year period [13] - For the nine-month period, operating expenses decreased significantly to $5.36 million, down $1.98 million or 27% from $7.34 million last year [14] Business Line Data and Key Metrics Changes - The company is advancing its Hemopurifier platform while maintaining disciplined cost control, with ongoing enrollment in the Australian oncology trial [5] - The second cohort of the oncology trial has seen two patients treated with Hemopurifier, with a third patient expected to be treated by the end of February [6][7] Market Data and Key Metrics Changes - There has been an uptick in the number of interested potential participants in the Australian oncology trial since contracting with TrialFax and Dedicated for recruitment [8] - The trial is designed to examine the number of Hemopurifier treatments needed to decrease extracellular vesicle concentrations and improve immune response against tumor cells [9] Company Strategy and Development Direction - The company is focused on advancing the Hemopurifier platform and exploring its compatibility with a simplified blood treatment system, which could enhance clinical and commercial flexibility [5][10] - Aethlon Medical is also exploring the potential of the Hemopurifier in treating conditions beyond oncology, including Long COVID and other diseases associated with extracellular vesicles [11][12] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the ongoing progress in the Australian oncology trial and the potential for the Hemopurifier to be integrated into oncology units and infusion centers, reducing invasiveness for patients [22][24] - The company is committed to cost containment while advancing its research and development efforts, particularly in the context of Long COVID [26] Other Important Information - The scientific rationale and full design of the Australian oncology trial have been published in a peer-reviewed journal, indicating the company's commitment to transparency and scientific rigor [10] - The next earnings call for the fiscal fourth quarter is scheduled to coincide with the filing of the annual report in June 2026 [16] Q&A Session Summary Question: Clarification on Cohort 2 treatment duration - Management confirmed that participants in Cohort 2 will receive two Hemopurifier treatments, maintaining the same follow-up period as Cohort 1 [19] Question: Impact of SLAMB system on treatment administration - The SLAMB system is expected to simplify the administration of Hemopurifier treatments, making it less invasive for patients and easier for hospital staff [22][24] Question: Cost-effective approach in R&D - Management emphasized the importance of cost containment while advancing research, focusing on in-house work and limiting external lab involvement [26] Question: Timeline for Data Safety Monitoring Board's decision - Management anticipates a decision from the Data Safety Monitoring Board on whether to advance to the third cohort on the same day or the next business day after the meeting [34] Question: Need for Cohort 3 - Management believes it is essential to conduct Cohort 3 to fully assess the efficacy of three treatments, based on historical data suggesting that more treatments may yield better results [60] Question: Regulatory hurdles for SLAMB system integration - The SLAMB system is not yet approved, and the company will need to conduct safety tests and treatments before integration with the Hemopurifier [45]

经济观察网沃特世(WAT.N)在完成与碧迪医疗(BD)生物科学与诊断解决方案业务的合并后股价出现显著 下跌，并创下60日新低。 合并后多家机构更新评级，目标价区间分歧较大(350美元至440美元)，例如花旗与巴克莱上调至"买 入"，但美银证券下调目标价至350美元并维持"持有"，反映市场对合并后增长路径存在分歧。同时，合 并后交易量显著放大(2月9日至11日日均成交额约11.4亿美元)，显示资金分歧加剧，可能放大股价波 动。 未来发展 管理层强调合并将强化公司在生物制药、诊断等高增长领域的布局，长期目标包括营收复合年增长率 7%及利润率扩张450个基点。但短期市场更关注整合风险(如业务重组、文化融合)及宏观环境(如利率政 策对高估值板块的压制)，导致股价与长期基本面出现背离。 以上内容基于公开资料整理，不构成投资建议。 财务状况 尽管沃特世2025财年营收同比增长6.99%，净利润微增0.75%，但2025年第四季度(截至2025年12月31日) 营收为9.32亿美元，净利润同比下滑2.67%。合并后市场可能关注短期整合成本及协同效应兑现进度， 例如公司预计3年内实现约20亿美元成本协同效应，但短期费用上升或 ...